Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Labiana HealthXMAD:LAB -0.75%57 PS Ratio is 0.64 as of Jul. 14, 2026, which is 68% above its 10-year median of 0.38. GuruFocus rates XMAD:LAB with a GF Score™ of 57/100 and a GF Value™ of €3.59 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 955 Drug Manufacturers companies, Labiana Health ranks better than 83.25% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Labiana Health's share price is €6.65.
Labiana Health's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €10.35. Hence, Labiana Health's PS Ratio for today is 0.64.
Warning Sign:
Labiana Health SA stock PS Ratio (=0.64) is close to 5-year high of 0.71.
The historical rank and industry rank for Labiana Health's PS Ratio or its related term are showing as below:
XMAD:LAB'
s PS Ratio Range Over the Past 10 Years
Min: 0.14 Med: 0.38 Max: 0.71
Current: 0.65
During the past 6 years, Labiana Health's highest PS Ratio was 0.71. The lowest was 0.14. And the median was 0.38.
XMAD:LAB's PS Ratio is ranked better than 83.25% of 955
companies
in the Drug Manufacturers industry
Industry Median: 2.33
vs XMAD:LAB: 0.65
During the past 12 months, the average Revenue per Share Growth Rate of Labiana Health was 16.50% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 10.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 5.60% per year.
During the past 6 years, Labiana Health's highest 3-Year average Revenue per Share Growth Rate was 10.10% per year. The lowest was 0.40% per year. And the median was 5.20% per year.
Back to Basics: PS Ratio
Labiana Health (XMAD:LAB) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Labiana Health PS Ratio Related Terms
Labiana Health PS Ratio Historical Data
* Premium members only.
The historical data trend for Labiana Health's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Labiana Health's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Labiana Health PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Labiana Health's PS Ratio distribution charts can be found below:
* The bar in red indicates where Labiana Health's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Labiana Health's Share Price of today is €6.65.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Labiana Health's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €10.35.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Labiana Health (XMAD:LAB) has a PS Ratio of 0.64 as of Jul. 14, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Labiana Health and its competitors. This is 68% above median its historical median of 0.38. Over the past decade, Labiana Health's PS Ratio has ranged from 0.14 to 0.71. According to the industry distribution chart, Labiana Health ranks #160 out of 955 companies in the Drug Manufacturers industry, placing it in the top 16.8%.
Is Labiana Health's PS Ratio too high?
Labiana Health's current PS Ratio of 0.64 is 68% above median its 10-year median of 0.38. Over the past 10 years, this metric has ranged from a low of 0.14 to a high of 0.71. The Drug Manufacturers industry median PS Ratio is 2.33. Labiana Health's value of 0.64 is 72.5% below this industry median. Based on the distribution chart, Labiana Health ranks #160 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Labiana Health has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Labiana Health's PS Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Labiana Health ranks #160 out of 955 companies for PS Ratio. This places Labiana Health in the top 17% of its industry — outperforming the majority of peers. The industry median PS Ratio is 2.33. Labiana Health's value of 0.64 is 72.5% below this benchmark. Historically, Labiana Health's own PS Ratio has ranged from 0.14 to 0.71 over the past decade. While the company's 10-year median is 0.38 vs. the industry median of 2.33, Labiana Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.33, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Labiana Health's current PS Ratio of 0.64 is 72.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Labiana Health and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labiana Health's current PS Ratio is 0.64, which is 68% above median its own 10-year median of 0.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labiana Health stock overvalued right now?
Based on GuruFocus' analysis, Labiana Health (XMAD:LAB) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.59, compared to a current price of €6.65 — trading 85.2% above its estimated fair value. The current PS Ratio is 0.64, which is 68% above median its 10-year median of 0.38 and 72.5% below the Drug Manufacturers industry median of 2.33. Labiana Health's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Labiana Health (XMAD:LAB), the current PS Ratio is 0.64 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Labiana Health (XMAD:LAB) Overvalued in 2026?
Based on GuruFocus' analysis, Labiana Health stock appears to be overvalued.
The current stock price of €6.65 is trading 85.2% above its estimated GF Value™ of €3.59.
GuruFocus considers Labiana Health to be Significantly Overvalued.
Key valuation signals for XMAD:LAB:
PS Ratio: 0.64 (68% above median its 10-year median of 0.38)
GF Value™: €3.59 vs. price of €6.65 (85.2% above fair value)
Industry Position: 72.5% below the Drug Manufacturers median (#160 of 955)
No single metric tells the full story. See the XMAD:LAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Labiana Health SA is a manufacturer of pharmacological products for veterinary use. The company's activities include a GMP manufacturer for EU animal and human health industries, a manufacturer specializing in sterile and lyophilized dosage forms, and a source of development, acquisition, and licensing of molecules such as Fosfomycin Trometamol. The company operates in two segment Animal Health and Human Health.
57GF Score
Get the complete analysis for XMAD:LAB
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:LAB has been successfully added to your 
